Drugs / MPC-5971
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00860093 | Apr → Nov 2010 | nephrolithiasis | Mission Pharmacal | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPC-5971 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00860093 ↗ |
| Modality | Small molecule | — CHEMBL4650302 ↗ |
| Route | Oral | “Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid).” NCT00860093 ↗ |